|
Appendix 3Y Brooke
|
16 June 2023 at 9:55am
|
|
Application for quotation of securities - ACR
|
16 June 2023 at 9:55am
|
|
4th FDA ANDA approval received - Dapsone Gel, 5%
|
7 June 2023 at 11:05am
|
|
Appendix 3Y Dobinson
|
24 May 2023 at 10:40am
|
|
Appendix 3Y Brumley
|
24 May 2023 at 10:40am
|
|
Application for quotation of securities - ACR
|
24 May 2023 at 10:35am
|
|
Quarterly Activities/Appendix 4C Cash Flow Report
|
26 April 2023 at 8:45am
|
|
Appendix 3Y Oldham
|
31 March 2023 at 9:55am
|
|
Appendix 3Y Brooke
|
31 March 2023 at 9:55am
|
|
Application for quotation of securities - ACR
|
31 March 2023 at 9:55am
|
|
Notification of cessation of securities - ACR
|
31 March 2023 at 9:35am
|
|
Appendix 3Y Buumley
|
9 March 2023 at 10:25am
|
|
Appendix 3Y Dobinson
|
1 March 2023 at 12:05pm
|
|
Appendix 3Y Brumley
|
1 March 2023 at 11:55am
|
|
Application for quotation of securities - ACR
|
1 March 2023 at 11:50am
|
|
Appendix 4D and Half Year Report
|
23 February 2023 at 1:00pm
|
|
Notification regarding unquoted securities - ACR
|
13 February 2023 at 2:05pm
|
|
Application for quotation of securities - ACR
|
13 February 2023 at 2:05pm
|
|
Quarterly Activities / Appendix 4C Cashflow Report
|
30 January 2023 at 9:45am
|
|
Gedeon Richter buyout Lenzetto Royalties for EUR4.1million
|
23 January 2023 at 9:25am
|
|
Positive FDA Remote Regulatory Assessment
|
19 January 2023 at 9:45am
|
|
Launch of prilocaine and lidocaine cream in United States
|
21 December 2022 at 8:50am
|
|
Mutual Termination of Co-Development Agreement
|
15 December 2022 at 11:55am
|
|
Appendix 3Y - Brooke
|
1 December 2022 at 9:40am
|
|
Appendix 3Y - Dobinson
|
1 December 2022 at 9:35am
|
|
Appendix 3Y - Brumley
|
1 December 2022 at 9:35am
|
|
Application for quotation of securities - ACR
|
1 December 2022 at 9:35am
|
|
Appendix 3Y Dobinson
|
25 November 2022 at 2:25pm
|
|
Appendix 3Y Brooke
|
25 November 2022 at 2:25pm
|
|
Appendix 3Y Oldham
|
25 November 2022 at 2:25pm
|
|
Appendix 3Y Brumley
|
25 November 2022 at 2:20pm
|
|
Notification regarding unquoted securities - ACR
|
25 November 2022 at 2:20pm
|
|
Results of AGM
|
23 November 2022 at 1:55pm
|
|
Chairman and CEO address to AGM
|
23 November 2022 at 8:45am
|
|
Final FY22 R&D Tax Incentive balance received (OSF)
|
3 November 2022 at 8:35am
|
|
Appendix 3Y Geoff Brooke
|
28 October 2022 at 9:45am
|
|
Appendix 3Y Ross Dobinson
|
28 October 2022 at 9:45am
|
|
Application for quotation of securities - ACR
|
28 October 2022 at 9:45am
|
|
Quarterly Activities/Appendix 4C Cash Flow Report
|
28 October 2022 at 9:30am
|
|
R&D Tax Incentive receipt - Overseas Finding
|
27 October 2022 at 10:20am
|
|
Notice of Annual General Meeting/Proxy Form
|
21 October 2022 at 8:45am
|
|
Application for quotation of securities - ACR
|
17 October 2022 at 9:35am
|
|
Remaining balance of R&D Tax Incentive Rebate received
|
3 October 2022 at 9:55am
|
|
R&D Tax Incentive Rebate received
|
26 September 2022 at 10:10am
|
|
Notification of cessation of securities - ACR
|
30 August 2022 at 8:50am
|
|
Appendix 3Y - Brumley
|
30 August 2022 at 8:50am
|
|
Application for quotation of securities - ACR
|
30 August 2022 at 8:45am
|
|
Appendix 4G and Corporate Governance Statement
|
26 August 2022 at 9:40am
|
|
Appendix 4E and FY22 Annual Report
|
26 August 2022 at 9:40am
|
|
Acrux's sixth generic dossier accepted by FDA for review
|
8 August 2022 at 9:59am
|
